Published on

Published in: Education, Technology, Business
No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide


  1. 1. Targeted Drug Delivery System LIPOSOMES
  2. 2. Learning Objectives <ul><li>Introduction </li></ul><ul><li>Mechanism of liposome formation </li></ul><ul><li>Classification of liposomes </li></ul><ul><li>Material used in preparation of liposomes </li></ul><ul><li>Methodes of liposome preparation </li></ul><ul><li>Characterization of liposomes </li></ul><ul><li>Stability </li></ul><ul><li>Therapeutic application </li></ul><ul><li>References </li></ul>
  3. 3. What are Liposomes? <ul><li>They are simply vesicles or ‘bags’ in which an aqueous volume is entirely enclosed by a membrane composed of lipid (fat) molecules, usually phospholipids. </li></ul>
  4. 4. <ul><li>These vesicles can encapsulate water-soluble drugs in their aqueous spaces and lipid soluble drug within the membrane itself. </li></ul><ul><li>The unique property of liposomes, namely their versatile, biodegradable, hypoallergenic nature, along with their similarity to biological membranes are the important factors in the continued efforts to develop liposomal drug delivery froms. </li></ul><ul><li>Structurally, liposomes are bilayered vesicles in which an aqueous volume is entirely enclosed by a membranous lipid bilayer mainly composed of natural or synthetic phospholipids . </li></ul>
  5. 5. Advantages of liposome : <ul><li>Provides selective passive targeting to tumor tissues </li></ul><ul><li>Increased efficacy and therapeutic index </li></ul><ul><li>Increased stability via encapsulation </li></ul><ul><li>Reduction in toxicity of the encapsulated agent. </li></ul><ul><li>Improved pharmacokinetic effects </li></ul><ul><li>Used as carriers for controlled and sustained drug delivery </li></ul><ul><li>Can be made into variety of sizes. </li></ul>
  6. 6. Disadvantages of liposome : <ul><li>Leakage of encapsulated drug during storage. </li></ul><ul><li>Uptake of liposomes by the reticuloendothelial system </li></ul><ul><li>Batch to batch variation </li></ul><ul><li>Difficult in large scale manufacturing and sterilization </li></ul><ul><li>Once administered, liposomes can not be removed </li></ul><ul><li>Possibility of dumping, due to faulty administration </li></ul>
  7. 7. Liposomes Evolution : <ul><li>1965 First description of closed lipid bilayer vesicles. </li></ul><ul><li>1967 introduction of the term liposomes to describe closed lipid bilayer vesicles </li></ul><ul><li>1972 liposomes first used as delivery systems of drugs </li></ul><ul><li>1974 first patients to be injected with liposomes </li></ul><ul><li>1979 liposomes first used as delivery systems of nucleic acids to cells </li></ul><ul><li>1980 first monoclonal anti body targeted liposomes termed imunoliposomes </li></ul>
  8. 8. <ul><li>1987 first synthetic cationic liposomes deliver genes to cells </li></ul><ul><li>1987 first sterically stabilized long circulating liposomes system introduced </li></ul><ul><li>1992 first lioposome based non viral vecrtor gene therapy clinical trail on cystic fibrosis patients </li></ul><ul><li>1993 frist liposome based vaccine against hepatitis A is marketed </li></ul><ul><li>1995 first long circulating immunoliposomes </li></ul><ul><li>1995 the liposomes encapsulated from of the anticancer drug doxorubicin and daunorubicin approved for human use </li></ul><ul><li>1997 first liposomes based DNA vaccine </li></ul>
  9. 9. Mechanism of liposome formation <ul><li>In order to understand why liposomes are formed when phospholipids are hydrated, it requires a basic understanding of physiochemical features of phospholipids. </li></ul><ul><li>Phospholipids are amphipathic molecules (having affinity for both aqueous and polar moieties) as they have a hydrophobic tail is composed of two fatty acids containing 10-24 carbon atoms and 0-6 double bonds in each chain. </li></ul>
  10. 10. <ul><li>In aqueous medium the phospholipid molecules are oriented in such a way that the polar portion of the molecule remains in contact with the polar environment and at the same shields the non-polar part. </li></ul><ul><li>They align themselves closely in planer bilayer sheets to minimize the interaction between the bulky aqueous phase and long hydrocarbon fatty acyl chains. </li></ul><ul><li>This alignment requires input of sufficient amount of energy (in the form of shaking, sonication, homogenization, heating, etc). </li></ul>
  11. 11. <ul><li>Interactions are completely eliminated when these sheets fold over themselves to form closed, sealed and continuous bilayer vesicles. </li></ul>
  12. 12. Classification of liposomes <ul><li>Multilamellar vesicles (MLVs) : consist of several bilayers and having size ranging from 100nm-20m </li></ul><ul><li>Small unilamellar vesicles (SUVs) : composed of single lipid bilayer with dimeter ranging from 20-100nm </li></ul><ul><li>Large unilamellar vesicles (LUVs) : consist of single bilayer with diameter ranging from 0.1-1m </li></ul><ul><li>Multivesicular vesicles (MVVs) : consist of vesicles with size ranging from 100nm-20m </li></ul>
  13. 14. Materials used in preparation of liposomes <ul><li>Phospholipids : </li></ul><ul><li>It is the major component of the biological membrane. </li></ul><ul><li>Two types of phospholipids are used natural and synthetic phospholipids. </li></ul><ul><li>The most common natural phospholipid is the phospatidylcholine (PC) is the amphipathic molecule and also known as lecithin. </li></ul><ul><li>It is originated from animal (hen egg) and vegetable (soyabean). </li></ul>
  14. 16. <ul><li>B. Steroids : </li></ul><ul><li>Cholesterol is generally used steroid in the formulation of liposomes. </li></ul><ul><li>It improves the fluidity of the bilayer membrane and reduces the permeability of bilayer membrane in the presence of biological fluids such as blood / plasma. </li></ul><ul><li>Cholesterol appers to reduce the interactions with blood proteins. </li></ul>
  15. 17. Methods of liposomes preparations Passive loading technique Active loading technique Mechanical dispersion methods Solvent dispersion methods Detergent removal methods
  16. 18. <ul><li>Mechanical dispersion methods </li></ul><ul><ul><li>Lipid is solublised in organic solvent, drug to be entrapped is solubilise in aqueous solvent, the lipid phase is hydrated at high speed stirring due to affinity of aqueous phase to polar head it is entrapped in lipid vesicles. </li></ul></ul><ul><ul><li>e.g. Lipid film hydration, Micro-emulsification ( Microfluidizer ), Sonication, Dried reconstituted vesicle </li></ul></ul>
  17. 19. <ul><li>Solvent dispersion methods </li></ul><ul><li>in this method, lipids are first dissolved in organic solvent, which then brought in to contact with aqueous phase containing material which is to be entrapped in liposome under rapid dilution and rapid evaporation of organic solvent. </li></ul><ul><li>e.g. </li></ul><ul><li>Ethanol injection </li></ul><ul><li>Ether injection </li></ul><ul><li>De-emulsification </li></ul><ul><li>Detergent removal methods </li></ul>
  18. 20. Physical Characterization Surface charge Free-flow electrophoresis Electrical surface potential and surface pH Zetapotential measurements & pH sensitive probes Percent of free drug/ percent capture Drug release Diffusion cell/ dialysis Parameter Characterization method Vesicle shape and surface morphology Mean vesicle size and size distribution Dynamic light scattering, zetasizer, Photon correlation spectroscopy, laser light scattering, gel permeation and gel exclusion Minicolumn centrifugation, ion-exchange chromatography,  radiolabelling Transmission electron microscopy, Freeze-fracture electron microscopy
  19. 21. Phopholipid peroxidation UV absorbance, Iodometric  and GLC Phospholipid hydrolysis, Cholesterol auto-oxidation HPLC and TLC Osmolarity Parameter Characterization method Phospholipid concentration Cholesterol concentration Cholesterol oxidase assay and HPLC Osmometer Barlett assay, stewart assay, HPLC Chemical Characterization
  20. 22. Biological Characterization Animal toxicity Monitoring survival rates, histology and pathology Parameter Characterization method Sterility Pyrogenicity Limulus Amebocyte Lysate (LAL) test Aerobic or anaerobic cultures
  21. 23. Stability <ul><li>Physical stability : </li></ul><ul><li>Once liposomes are formed, they behave similar to the other colloidal particles suspended in water. </li></ul><ul><li>Neutral particles tend to aggregate or flocculate and sediment with increase in size on storage. Adding charged lipids such as stearyl amine, diactyl phosphate and phosphatidyl serine can control the aggregation. </li></ul><ul><li>The addition of charged lipids causes repulsion and prevents major changes in the overall size of liposomes. </li></ul>
  22. 24. <ul><li>Chemical stability : </li></ul><ul><li>Phospholipids, especially those derived from natural sources, are subject to two major degradative reaction : </li></ul><ul><li>A. Lipid peroxidation : most phospolipid liposomes contain unsaturated acyl chains as part of their molecular structure and susceptible to oxidative degradation. It can be minimized by the use of animal derived lipids like egg PC, which has less saturated lipids, use of light resistant containers, use of antioxidants are useful in minimizing oxidation. </li></ul>
  23. 25. <ul><li>B. Lipid hydrolysis : </li></ul><ul><li>hydrolysis in phospolipids results in the formation of free fatty acids and lyso-lecithin. Selecting a good source of lipid, temperature, pH, and minimizing oxidation. </li></ul><ul><li>Biological stability : </li></ul><ul><li>liposomes release entrapped molecules rapidly when incubated with blood or plasma. This instability is attributed to the transfer of bilayer lipids to albumin and high density liposomes. </li></ul>
  24. 26. Therapeutic applications of liposomes <ul><li>Liposomes as drug / protein delivery vehicles </li></ul><ul><li>Controlled and sustain release in situ </li></ul><ul><li>Enhanced drug solubilization </li></ul><ul><li>Enzyme replacement therapy and lysosomal storage disorders </li></ul><ul><li>Altered pharmacokinetics and biodistribution </li></ul><ul><li>Liposomes in antimicrobial, antifungal and antiviral therapy </li></ul><ul><li>Liposomes in tumour therapy </li></ul><ul><li>Carrier of small cytotoxic molecules </li></ul><ul><li>Vehicle for macromolecules as cytokines and genes </li></ul>
  25. 27. <ul><li>Liposomes in gene delivery </li></ul><ul><li>Genes and antisense therapy </li></ul><ul><li>Genetic (DNA) vaccination </li></ul><ul><li>Liposomes in immunology </li></ul><ul><li>Liposomes as radiopharmaceutical and radio diagnostic carrier </li></ul><ul><li>Liposomes in cosmetic and dermatology </li></ul><ul><li>Liposomes in enzyme immobilization and bioractor technology </li></ul>
  26. 28. Pseudomonas infection, aeruginosa Pulmonary delivery Tobramycin Asthma Pulmonary delivery Pentoxyfylline Pain muscle condition Ocular delivery   Ketoprofen Diabetic mellitus Oral, Ocular, Pulmonary and Transdermal delivery   Insulin Mycotic infection Oral delivery Amphotericin-B Targeted Diseases Route of administration Drug
  27. 29. Cancer Transdermal Methotrexate Meningococal, staphylococcal Pulmonary delivery Penicillin G Glucoma, Conjectivitis Ocular delivery Adrenaline Rheumatoid arthritis Oral delivery Ibuprofen ulcer on mucous surface with pain Transdermal Benzocain Asthma Pulmonary delivery Salbutamol Targeted Diseases Route of administration Drug
  28. 30. Britannia Pharm, UK Expanding lung diseases in babies Dry protein free powder of DPPC-PG ALECTM The liposome company, USA Systemic inflammatory diseases Prostaglandin-E1 VENTUSTM SEQUUS, USA fungal infections, Leishmaniasis Amphotericin-B AmphotecTM NeXstar, USA Kaposi’s sarcoma, breast & lung cancer Daunorubicin DaunoXomeTM SEQUUS, USA Kaposi’s sarcoma Doxorubicin DoxilTM or CaelyxTM Company Target diseases Drug used Marketed product
  29. 31. Swiss serum & vaccine institute, Switzerland Hepatitis A Inactivated hepatitis-A Virions Epaxal –Berna Vaccine Vineland lab, USA Chicken pox Killed avian retrovirus Avian retrovirus vaccine Novavax, USA Smallpox Smallpox vaccine Novasome® Skye Pharm, USA Cancer therapy Cytarabine Depocyt Ozone, USA Asthma Terbutaline sulphate Topex-Br Company Target diseases Drug used Marketed product
  30. 32. Conclusion <ul><li>Liposomes are one of the unique drug delivery system, which can be of potential use in controlling and targeting drug delivery. </li></ul><ul><li>Liposomes are administrated orally, parenterally and topically as well as used in cosmetic and hair technologies, sustained release formulations, diagnostic purpose and as good carriers in gene delivery. </li></ul><ul><li>Nowadays liposomes are used as versatile carriers for targeted delivery of drug. </li></ul>
  31. 33. Reference <ul><li>Targeted and controlled drug delivery, S.P.Vyas and R.K.Khar, CBS Publication 2008, </li></ul><ul><li>Nanoparticles – page no 331 to 386. </li></ul><ul><li>Resealed Erythrocytes – page no 387 to 416. </li></ul><ul><li>Liposomes – page no 173 to 248. </li></ul><ul><li>Text book of Industrial Pharmacy, Shobha Rani Hiremath, Orient Longman Private ltd. </li></ul><ul><li>Nanoparticles – 129 to 142. </li></ul><ul><li>Liposomes – 97 to 110 </li></ul>
  32. 34. <ul><li>Medical applications of nanotechnology by Timothy E. Morey, University of Florida. </li></ul><ul><li>Liposome: A versatile platform for targeted delivery of drugs by Sanjay S. Patel </li></ul><ul><li>Resealed Erythrocytes : A Review by A.V.Gothoskar MIT Campus, Pune. </li></ul><ul><li> </li></ul><ul><li> </li></ul>
  33. 35. Any question...
  34. 36. Thank You